This suggests that the level of sensitivity to kinase inhibition that is conferred by gene fusions like BCR::ABL1 for Ph+ ALL may not be conferred by point mutations in JAK1 and JAK2 for Ph-like ALL. This evidence concerns the gene BCR and acute lymphoblastic leukemia.